2月11日 - ** 肥胖症药物开发商Viking Therapeutics VKTX.O盘后股价上涨9.4%至31.24美元
** VKTX表示，它计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段
** 公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的一个重要因素，因为目前还没有其他双效或三效激动剂同时提供这两种剂型” - VKTX
** 后期研究结果表明，VK2735 口服片剂每日一次，13 周后体重平均下降达 12.2%。
** 2025 年，VKTX 下降了 12.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.